Business Context and Reporting Period
This Form 8-K is filed by Gemphire Therapeutics Inc. (not Metavia Inc.) on November 2, 2016. The report discloses the issuance of a press release detailing financial results for the third quarter ended September 30, 2016.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the provided text.
Material Changes
The filing text does not provide data to compare current period results against prior comparable periods. No specific material changes are detailed in the body of this 8-K.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, risk factors, or details on contingencies and unusual items. The document serves solely as a notification that the Q3 2016 results have been released via a press release.
Investor Verification Checklist
- Verify the correct registrant name is Gemphire Therapeutics Inc., as the input metadata incorrectly listed "Metavia Inc."
- Retrieve and review Exhibit 99.1 (Press Release dated November 2, 2016) to obtain actual financial figures for the quarter ended September 30, 2016.
- Confirm the company's principal executive office location in Livonia, Michigan, and contact details.